Background to InRange study: Richard M Bergenstal
Glycated haemoglobin has been considered as a gold standard for measuring glycemic control. However, it is unable to measure the levels of glycemic excursions. Glycemic variability puts patients with diabetes at the risk of micro- and macrovascular complications. Continuous glucose monitoring (CGM) is one tool that helps assess the level of variability and this helps to manage diabetes better, with improved glucose control, reduced GV and better TIR. Let us find out what the InRange study wants to say in this respect. InRange study is the comparison of the second-generation basal insulin analogues glargine 300 U/mL and degludec 100 U/mL in persons with type 1 diabetes using continuous glucose monitoring. New metrics such as TIR and %CV have emerged from the development of CGM technology, helping to support clinicians and patients with daily diabetes management and assessment of glycemic control. InRange is the first RCT in adults with type 1 diabetes to compare Gla-300 and IDeg-100, with TIR as the primary endpoint and glycemic variability as the main secondary endpoint.